Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | LATS1 | O95835 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7607045 | 0.92 | EGFR (0.48) | EGFRLATS1GBA1KDM4EGAA | |
| SCHEMBL7612727 | 0.86 | NUDT1 (0.49) | EGFRLATS1GBA1KDM4ECYP11B1 | |
| SCHEMBL7611890 | 0.85 | ALDH1A1 (0.55) | EGFRLATS1GBA1KDM4EGAA | |
| SCHEMBL7610178 | 0.84 | PDE5A (0.48) | LATS1GBA1KDM4EGAACSNK2A1 | |
| SCHEMBL9268502 | 0.82 | LATS1 (0.43) | EGFRLATS1GBA1KDM4EGAA | |
| SCHEMBL7606449 | 0.82 | LATS1 (0.43) | EGFRLATS1GBA1KDM4EGAA | |
| SCHEMBL7604925 | 0.82 | LATS1 (0.43) | EGFRLATS1GBA1KDM4EGAA | |
| SCHEMBL7611430 | 0.79 | LATS1 (0.64) | LATS1GBA1KDM4EGAAPKM | |
| SCHEMBL7609138 | 0.79 | LATS1 (0.40) | LATS1KDM4EGAACYP19A1HTT | |
| SCHEMBL7610824 | 0.78 | NUDT1 (0.49) | LATS1GBA1CSNK2A1CSNK2A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | EGFR 3506/4885LATS1 674/4885GBA1 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.